.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,797,732

« Back to Dashboard
Patent 6,797,732 protects STALEVO 100, STALEVO 125, STALEVO 150, STALEVO 200, STALEVO 50, and STALEVO 75, and is included in one NDA. There have been zero Paragraph IV challenges on Stalevo 75, Stalevo 125, Stalevo 200, Stalevo 50, Stalevo 100, and Stalevo 150.

This patent has fifty-two patent family members in forty countries.

Summary for Patent: 6,797,732

Title: Pharmaceutical composition comprising entracapone, levodopa, and carbidopa
Abstract:An oral solid fixed dose composition comprising pharmacologically effective amounts of entacapone, levodopa, and carbidopa, or pharmaceutically acceptable salts or hydrates thereof, and comprising at least one pharmaceutically acceptable excipient. The composition can be used, e.g., for the treatment of Parkinson's disease.
Inventor(s): Virkki; Matti (Masala, FI), Vahervuo; Kari (Espoo, FI), Ritala; Marja (Espoo, FI), Partanen; Marja (Espoo, FI), Niskanen; Mervi (Espoo, FI), Lintulaakso; Jarmo (Espoo, FI), Laaksonen; Marja (Masala, FI), Kervinen; Lasse (Helsinki, FI), Kallioinen; Sari (Espoo, FI)
Assignee: Orion Corporation (Espoo, FI)
Application Number:10/223,298
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form;
Patent Metrics:
Source: PatentQuant.com
Field: Basic materials chemistry
Back Citations: 11th percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Orion Pharma
STALEVO 100
carbidopa; entacapone; levodopa
TABLET;ORAL021485-002Jun 11, 2003RXNo6,797,732► subscribeY
Orion Pharma
STALEVO 125
carbidopa; entacapone; levodopa
TABLET;ORAL021485-006Aug 29, 2008RXNo6,797,732► subscribeY
Orion Pharma
STALEVO 150
carbidopa; entacapone; levodopa
TABLET;ORAL021485-003Jun 11, 2003RXNo6,797,732► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,797,732

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Finland991485Jun 30, 1999

Non-Orange Book Patents for Patent: 6,797,732

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,500,867 Pharmaceutical composition comprising entacapone, levodopa, and carbidopa► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,797,732

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Hungary0202273► subscribe
Israel146807► subscribe
ItalyMI20001450► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc